1. Scrip
  2. >>Business

Clinigen Takes Aim At Unlicensed-To-Licensed Strategy With Quantum Buy

 
• By John Davis

Extending its business in continental Europe, in niche generics and in the further development of unlicensed medicines are some of the drivers of Clinigen's latest proposed acquisition.

Target
Some patients need unlicensed medicines for their condition • Source: Shutterstock.

The UK pharmaceutical services company. Clinigen Group PLCis planning to acquire Quantum Pharma PLC in a cash-and-share deal valued at £150.3m ($199.5m), enlarging Clinigen's activities in the ethical supply of unlicensed medicines in the UK and continental Europe, and strengthening its role in commercializing medicine.

The interest of Clinigen in Quantum became public in the middle of last month, and the two AIM-listed companies have...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Shigella Vaccine Pipeline And Why It Matters

 
• By Vibha Ravi

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease, which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project.

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Xu Hu

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.